1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours

• DOI: 10.1016/j.annonc.2024.08.1313
• Publication Date: 2024-09-17T20:27:28Z
• Authors: B. Besse; A.E. Drilon; B.C. Cho; D.R. Camidge; J. Neal; C-C. Lin; S.V. Liu; M. Nagasaka; S.C-H. Kao; E. Felip; A.J. Van Der Wekken; C.C. Lin; J.R. Bauman; S. Gadgeel; M. Samant; J. Shen; Y. Sun; V.W. Zhu; V.A. Upadhyay; J.J. Lin